| SC 13G/A | 2024-02-14 | BIOTECHNOLOGY VALUE FUND L P | CytomX Therapeutics, Inc. | 3,651,391 | 5.4% | EDGAR |
| SC 13G/A | 2024-02-14 | TANG CAPITAL PARTNERS LP | CytomX Therapeutics, Inc. | 6,550,000 | 9.8% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | CytomX Therapeutics, Inc. | 4,902,943 | 7.3% | EDGAR |
| SC 13G/A | 2023-02-14 | Point72 Asset Management, L.P. | CytomX Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | RTW INVESTMENTS, LP | CytomX Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | TANG CAPITAL PARTNERS LP | CytomX Therapeutics, Inc. | 3,510,445 | 5.3% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | CytomX Therapeutics, Inc. | 4,585,721 | 6.9% | EDGAR |
| SC 13G/A | 2022-07-29 | BIOTECHNOLOGY VALUE FUND L P | CytomX Therapeutics, Inc. | 3,544,303 | 5.4% | EDGAR |
| SC 13G | 2022-07-25 | TANG CAPITAL PARTNERS LP | CytomX Therapeutics, Inc. | 3,470,900 | 5.3% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | CytomX Therapeutics, Inc. | 1,826,591 | 2.8% | EDGAR |
| SC 13G/A | 2022-02-14 | Point72 Asset Management, L.P. | CytomX Therapeutics, Inc. | 6,303,025 | 9.7% | EDGAR |
| SC 13G/A | 2022-02-14 | RTW INVESTMENTS, LP | CytomX Therapeutics, Inc. | 6,029,700 | 9.2% | EDGAR |
| SC 13G/A | 2022-02-14 | RA CAPITAL MANAGEMENT, L.P. | CytomX Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-09 | VANGUARD GROUP INC | CytomX Therapeutics, Inc. | 5,107,991 | 7.8% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | CytomX Therapeutics, Inc. | 4,962,362 | 7.6% | EDGAR |
| SC 13G/A | 2022-02-01 | VICTORY CAPITAL MANAGEMENT INC | CytomX Therapeutics, Inc. | 8,828 | 0.0% | EDGAR |
| SC 13G | 2022-01-03 | BIOTECHNOLOGY VALUE FUND L P | CytomX Therapeutics, Inc. | 3,002,559 | 4.6% | EDGAR |
| SC 13G | 2021-12-08 | RTW INVESTMENTS, LP | CytomX Therapeutics, Inc. | 5,868,326 | 9.0% | EDGAR |
| SC 13G/A | 2021-05-03 | BIOTECHNOLOGY VALUE FUND L P | CytomX Therapeutics, Inc. | 1,555,009 | 2.4% | EDGAR |
| SC 13G/A | 2021-02-16 | PERCEPTIVE ADVISORS LLC | CytomX Therapeutics, Inc. | 2,577,043 | 4.3% | EDGAR |